Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia

• Published in: Blood Vol. 117; no. 8; pp. 2340 - 2347
• Main Authors: Kawedia, Jitesh D., Kaste, Sue C., Pei, Deqing, Panetta, John C., Cai, Xiangjun, Cheng, Cheng, Neale, Geoffrey, Howard, Scott C., Evans, William E., Pui, Ching-Hon, Relling, Mary V.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 24-02-2011; Americain Society of Hematology; American Society of Hematology
• Series: Clinical Trials and Observations
• Subjects: Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - pharmacokinetics; Biological and medical sciences; Child; Clinical Trials and Observations; Dexamethasone; Diseases of the osteoarticular system; Genome-Wide Association Study; Hematologic and hematopoietic diseases; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Magnetic Resonance Imaging - methods; Medical sciences; Osteonecrosis - chemically induced; Osteonecrosis - etiology; Osteonecrosis - genetics; Pharmacogenetics; Pharmacokinetics; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Prednisone; Prospective Studies; Risk Factors; Vascular bone diseases; Human; Pharmacogenetics; Pharmacodynamics; Hematology; Diseases of the osteoarticular system; Malignant hemopathy; Osteonecrosis; Lymphoproliferative syndrome; Genetics; Acute lymphocytic leukemia; Pharmacokinetics; Child; Cancer
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2010-10-311969

Osteonecrosis is a severe glucocorticoid-induced complication of acute lymphoblastic leukemia treatment. We prospectively screened children (n = 364) with magnetic resonance imaging of hips and knees, regardless of symptoms; the cumulative incidence of any (grade 1-4) versus symptomatic (grade 2-4) osteonecrosis was 71.8% versus 17.6%, respectively. We investigated whether age, race, sex, acute lymphoblastic leukemia treatment arm, body mass, serum lipids, albumin and cortisol levels, dexamethasone pharmacokinetics, and genome-wide germline genetic polymorphisms were associated with symptomatic osteonecrosis. Age more than 10 years (odds ratio, = 4.85; 95% confidence interval, 2.5-9.2; P = .00001) and more intensive treatment (odds ratio = 2.5; 95% confidence interval, 1.2-4.9; P = .011) were risk factors and included as covariates in all analyses. Lower albumin (P = .05) and elevated cholesterol (P = .02) associated with symptomatic osteonecrosis, and severe (grade 3 or 4) osteonecrosis was linked to poor dexamethasone clearance (P = .0005). Adjusting for clinical features, polymorphisms of ACP1 (eg, rs12714403, P = 1.9 × 10−6, odds ratio = 5.6; 95% confidence interval, 2.7-11.3), which regulates lipid levels and osteoblast differentiation, were associated with risk of osteonecrosis as well as with lower albumin and higher cholesterol. Overall, older age, lower albumin, higher lipid levels, and dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic variation.